228 related articles for article (PubMed ID: 27333028)
1. Structure-Based Drug Discovery for Prion Disease Using a Novel Binding Simulation.
Ishibashi D; Nakagaki T; Ishikawa T; Atarashi R; Watanabe K; Cruz FA; Hamada T; Nishida N
EBioMedicine; 2016 Jul; 9():238-249. PubMed ID: 27333028
[TBL] [Abstract][Full Text] [Related]
2. Novel Compounds Identified by Structure-Based Prion Disease Drug Discovery Using In Silico Screening Delay the Progression of an Illness in Prion-Infected Mice.
Ishibashi D; Ishikawa T; Mizuta S; Tange H; Nakagaki T; Hamada T; Nishida N
Neurotherapeutics; 2020 Oct; 17(4):1836-1849. PubMed ID: 32767031
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Anti-prion Compounds Using In Silico and In Vitro Approaches.
Hyeon JW; Choi J; Kim SY; Govindaraj RG; Jam Hwang K; Lee YS; An SS; Lee MK; Joung JY; No KT; Lee J
Sci Rep; 2015 Oct; 5():14944. PubMed ID: 26449325
[TBL] [Abstract][Full Text] [Related]
4. A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.
Ferreira NC; Ascari LM; Hughson AG; Cavalheiro GR; Góes CF; Fernandes PN; Hollister JR; da Conceição RA; Silva DS; Souza AMT; Barbosa MLC; Lara FA; Martins RAP; Caughey B; Cordeiro Y
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133563
[TBL] [Abstract][Full Text] [Related]
5. A Small-Molecule Inhibitor of Prion Replication and Mutant Prion Protein Toxicity.
Massignan T; Sangiovanni V; Biggi S; Stincardini C; Elezgarai SR; Maietta G; Andreev IA; Ratmanova NK; Belov DS; Lukyanenko ER; Belov GM; Barreca ML; Altieri A; Kurkin AV; Biasini E
ChemMedChem; 2017 Aug; 12(16):1286-1292. PubMed ID: 28722340
[TBL] [Abstract][Full Text] [Related]
6. Identification of Alprenolol Hydrochloride as an Anti-prion Compound Using Surface Plasmon Resonance Imaging.
Miyazaki Y; Ishikawa T; Kamatari YO; Nakagaki T; Takatsuki H; Ishibashi D; Kuwata K; Nishida N; Atarashi R
Mol Neurobiol; 2019 Jan; 56(1):367-377. PubMed ID: 29704200
[TBL] [Abstract][Full Text] [Related]
7.
Eraña H; Fernández-Borges N; Elezgarai SR; Harrathi C; Charco JM; Chianini F; Dagleish MP; Ortega G; Millet Ó; Castilla J
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978705
[TBL] [Abstract][Full Text] [Related]
8. Transient multimers modulate conformer abundances of prion protein monomer through conformational selection.
Van der Rest G; Rezaei H; Halgand F
Sci Rep; 2019 Aug; 9(1):12159. PubMed ID: 31434938
[TBL] [Abstract][Full Text] [Related]
9. Virus Infection, Genetic Mutations, and Prion Infection in Prion Protein Conversion.
Hara H; Sakaguchi S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830321
[TBL] [Abstract][Full Text] [Related]
10. Discovery of small molecules binding to the normal conformation of prion by combining virtual screening and multiple biological activity evaluation methods.
Li L; Wei W; Jia WJ; Zhu Y; Zhang Y; Chen JH; Tian J; Liu H; He YX; Yao X
J Comput Aided Mol Des; 2017 Dec; 31(12):1053-1062. PubMed ID: 29159521
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a simple cell-based ELISA for the direct detection of abnormal isoform of prion protein from prion-infected cells without cell lysis and proteinase K treatment.
Shan Z; Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
Prion; 2016 Jul; 10(4):305-18. PubMed ID: 27565564
[TBL] [Abstract][Full Text] [Related]
12. In silico studies and fluorescence binding assays of potential anti-prion compounds reveal an important binding site for prion inhibition from PrP(C) to PrP(Sc).
Pagadala NS; Perez-Pineiro R; Wishart DS; Tuszynski JA
Eur J Med Chem; 2015 Feb; 91():118-31. PubMed ID: 25042003
[TBL] [Abstract][Full Text] [Related]
13. Structural Consequences of Copper Binding to the Prion Protein.
Salzano G; Giachin G; Legname G
Cells; 2019 Jul; 8(8):. PubMed ID: 31349611
[TBL] [Abstract][Full Text] [Related]
14. N-Terminal Regions of Prion Protein: Functions and Roles in Prion Diseases.
Hara H; Sakaguchi S
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872280
[TBL] [Abstract][Full Text] [Related]
15. Application of the fragment molecular orbital method to discover novel natural products for prion disease.
Choi J; Kim HJ; Jin X; Lim H; Kim S; Roh IS; Kang HE; No KT; Sohn HJ
Sci Rep; 2018 Aug; 8(1):13063. PubMed ID: 30166585
[TBL] [Abstract][Full Text] [Related]
16. Intermolecular crosslinking of abnormal prion protein is efficiently induced by a primuline-sensitized photoreaction.
Teruya K; Nishizawa K; Oguma A; Sakasegawa Y; Kitamoto T; Doh-Ura K
Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):384-394. PubMed ID: 30447252
[TBL] [Abstract][Full Text] [Related]
17. A simple in vitro assay for assessing the efficacy, mechanisms and kinetics of anti-prion fibril compounds.
Ladner-Keay CL; Ross L; Perez-Pineiro R; Zhang L; Bjorndahl TC; Cashman N; Wishart DS
Prion; 2018; 12(5-6):280-300. PubMed ID: 30223704
[TBL] [Abstract][Full Text] [Related]
18. The compound (3-{5-[(2,5-dimethoxyphenyl)amino]-1,3,4-thiadiazolidin-2-yl}-5,8-methoxy-2H-chromen-2-one) inhibits the prion protein conversion from PrP
Pagadala NS; Bjorndahl TC; Joyce M; Wishart DS; Syed K; Landi A
Bioorg Med Chem; 2017 Oct; 25(20):5875-5888. PubMed ID: 28951092
[TBL] [Abstract][Full Text] [Related]
19. Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance.
Colini Baldeschi A; Zattoni M; Vanni S; Nikolic L; Ferracin C; La Sala G; Summa M; Bertorelli R; Bertozzi SM; Giachin G; Carloni P; Bolognesi ML; De Vivo M; Legname G
J Med Chem; 2022 Jul; 65(13):8998-9010. PubMed ID: 35771181
[TBL] [Abstract][Full Text] [Related]
20. Transition of the prion protein from a structured cellular form (PrP
Baral PK; Yin J; Aguzzi A; James MNG
Protein Sci; 2019 Dec; 28(12):2055-2063. PubMed ID: 31583788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
